37.02

2.15% 0.78

After Hours: 37.02

Ideaya Biosciences Inc (IDYA)

Overview News Price History Option Chain Financials Discussions Forecast

Ideaya Biosciences Inc stock is traded at $37.02, with a volume of 602.28K. It is up +2.15% in the last 24 hours and down -8.62% over the past month. IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Previous Close:

$36.24

Open:

$36.5

24h Volume:

602.28K

Relative Volume:

0.55

Market Cap:

$3.56B

Revenue:

$225.27M

Net Income/Loss:

$-140.06M

P/E Ratio:

-23.18

EPS:

-1.5974

Net Cash Flow:

$-87.93M

1W Performance:

+4.28%

1M Performance:

-8.62%

6M Performance:

+15.08%

1Y Performance:

+65.19%

1-Day Range:

$36.27

$37.03

1-Week Range:

$34.56

$37.03

52-Week Range:

$22.22

$40.58

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name

Ideaya Biosciences Inc

Sector

Healthcare (1077)

Industry

Biotechnology (602)

Phone

650-443-6209

Address

5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA

Employee

145

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

IDYA's Discussions on Twitter

Compare IDYA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IDYA Ideaya Biosciences Inc	37.02	3.54B	225.27M	-140.06M	-87.93M	-1.5974
VRTX Vertex Pharmaceuticals Inc	496.07	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	784.36	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	865.04	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	205.15	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	348.27	33.81B	5.76B	514.49M	1.10B	4.4813

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Resumed	UBS	Buy
Nov-24-25	Initiated	Truist	Buy
Sep-18-25	Initiated	Guggenheim	Buy
Sep-04-25	Initiated	Barclays	Overweight
Sep-04-25	Initiated	Citizens JMP	Mkt Outperform
Jul-22-25	Initiated	TD Cowen	Buy
Jul-10-25	Resumed	Goldman	Neutral
Jun-26-25	Initiated	Wells Fargo	Overweight
Nov-18-24	Initiated	Stephens	Overweight
Nov-05-24	Downgrade	Leerink Partners	Outperform → Market Perform
Oct-24-24	Initiated	UBS	Buy
Oct-15-24	Initiated	Cantor Fitzgerald	Overweight
Jul-08-24	Initiated	Mizuho	Outperform
Mar-08-24	Initiated	BTIG Research	Buy
Aug-08-23	Initiated	SVB Securities	Outperform
May-24-23	Initiated	Goldman	Buy
Apr-24-23	Upgrade	Stifel	Hold → Buy
Mar-23-23	Initiated	Berenberg	Buy
Feb-28-23	Initiated	RBC Capital Mkts	Outperform
Dec-28-22	Initiated	CapitalOne	Overweight
Oct-27-22	Initiated	Citigroup	Buy
Aug-15-22	Downgrade	Stifel	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform
Mar-10-22	Upgrade	Stifel	Hold → Buy
Sep-23-21	Initiated	Stifel	Hold
Jun-04-21	Resumed	Robert W. Baird	Outperform
Mar-11-21	Initiated	Guggenheim	Buy
Oct-07-20	Initiated	Wedbush	Outperform
Sep-01-20	Initiated	Northland Capital	Outperform
Jul-13-20	Upgrade	JP Morgan	Neutral → Overweight
Jun-17-20	Reiterated	H.C. Wainwright	Buy
Apr-06-20	Initiated	H.C. Wainwright	Buy
Mar-13-20	Initiated	ROTH Capital	Buy
Oct-17-19	Initiated	Oppenheimer	Outperform
Sep-10-19	Initiated	Robert W. Baird	Outperform
Jun-17-19	Initiated	Citigroup	Buy
Jun-17-19	Initiated	JP Morgan	Neutral
Jun-17-19	Initiated	Jefferies	Buy

View All

Ideaya Biosciences Inc Stock (IDYA) Latest News

Jul 27, 2026

LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo

Jul 27, 2026

IDEAYA initiates expansion phase for cancer drug IDE892 By Investing.com - Investing.com Canada

Jul 27, 2026

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers - PR Newswire

Jul 27, 2026

Jul 25, 2026